Journal
LUNG CANCER
Volume 42, Issue -, Pages S47-S51Publisher
ELSEVIER SCI IRELAND LTD
DOI: 10.1016/S0169-5002(03)00304-0
Keywords
adjuvant chemotherapy; combined modality therapy; non-small cell lung cancer; surgery
Categories
Ask authors/readers for more resources
Less than 20-25% of non-small cell lung cancer (NSCLC) patients present with stage I or II disease are best treated by surgical resection. Long-term survival in NSCLC remains poor also in these early stages: the 5-year survival rate of patients who undergo complete surgical resection is only 40 to 50%. The majority of post-surgical relapses are distant metastases with the risk of a local recurrence after complete resection being less than 10%. Postoperative treatments, including chemotherapy, radiotherapy or both, have been widely evaluated during the last decades and, unfortunately, none has demonstrated any significant impact on survival. Data regarding large-scale adjuvant chemotherapy trials, closed for the accrual almost four to five years ago, will be fully available soon and, hopefully, a specific meta-analysis will be performed. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available